An analysis in Kenya found that, although the government will need to more than double its current vaccine budget to continue using PCV after GAVI support ends, continuing the vaccination will prevent more than 101,000 cases of invasive pneumoccocal disease and pneumonia, more than 14,000 deaths over an 11-year period, and would be cost-effective (cost per DALY of $153 by 2032), even at the full GAVI price of US $3.05 per dose.
Full Citation:
Ojal J, Griffiths U, Hammitt LL et al.. 2019. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya. Lancet Global Health. 7(5).
Title of Article: Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya
Author(s): Ojal J, Griffiths U, Hammitt LL et al.
Publication Year: 2019
Publication Name: Lancet Global Health
Publication Volume: 7(5)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/31000132/
DOI (Digital Object Identifier): 10.1016/S2214-109X(18)30562-X
Topics: Economics & Return on Investment
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Immunization Terms: Cost-effectiveness
Countries: Kenya
WHO Regions: Africa